NewsBenzinga安进和阿斯利康药物联合疗法在难治性肺癌中显示出有前景的生存结果 安进和阿斯利康药物联合疗法在难治性肺癌中显示出有前景的生存结果 Benzinga 2026.10.26 13:23 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report